Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting

Raf

Raf is a family of three serine/threonine-specific protein kinases that are related to retroviral oncogenes.

Items 1-10 of 13

Page
per page
  1. Vemurafenib (PLX4032, RG7204)
    A3004 Vemurafenib (PLX4032, RG7204)
     9 Citation
    Target: Raf
    Summary: BRAF kinase inhibitor
      ≥24.5 mg/mL
  2. Sorafenib
    A3009 Sorafenib
     2 Citation
    Target: Raf|VEGFR
    Summary: Raf kinases and tyrosine kinases inhibitor
      ≥23.25 mg/mL
  3. PLX-4720
    A3016 PLX-4720
     1 Citation
    Target: Raf
    Summary: BRAF kinase inhibitor
      ≥20.69 mg/mL
  4. Dabrafenib Mesylate (GSK-2118436)
    A3347 Dabrafenib Mesylate (GSK-2118436)
    Target: Raf
    Summary: Inhibitor of BRAF(V600) mutants
      ≥30.75 mg/mL
  5. TAK-632
    A8226 TAK-632
    Target: Raf
    Summary: Pan-RAF inhibitor,potent and selective
      ≥27.75 mg/mL
  6. Sorafenib Tosylate
    A8245 Sorafenib Tosylate
     1 Citation
    Target: Raf|VEGFR
    Summary: Raf kinases and tyrosine kinases inhibitor
      ≥31.85 mg/mL
  7. GDC-0879
    A5071 GDC-0879
     1 Citation
    Target: Raf
    Summary: B-Raf inhibitor,potent and selective
      insoluble in EtOH; insoluble in H2O; ≥16.7 mg/mL
  8. RAF265
    A8313 RAF265
    Target: Raf|VEGFR
    Summary: Multiple intracellular kinases inhibitor
      ≥25.9 mg/mL
  9. BI-D1870
    B2227 BI-D1870
     1 Citation
    Target: p90 S6K
    Summary: P90 RSK inhibitor,ATP-competitive and cell-permeable
      insoluble in H2O; ≥19.55 mg/mL
  10. GW5074
    B1405 GW5074
    Summary: C-Raf inhibitor,potent and selective
      insoluble in EtOH; insoluble in H2O; ≥21.9 mg/mL

Items 1-10 of 13

Page
per page